Abida et al. reported that 7 of 32 patients with MSI-H or dMMR prostate cancer had a potential pathogenic germline mutation in MMR-associated genes, including MSH2 (n = 5), MSH6 (n = 1), and PMS2 (n = 1). The gene discussed is MSH2; the disease is prostate carcinoma.